Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Quarter read is okay, I don't agree with the Projected # when you watched the water tower Event Benic Mentioned better Numbers then 16 Million. Be careful the Next surprise is a 3 for 1 rev. split... Good Day.. still holding!
Ndakota
FUN sorry if it sounded towards your write up. I meant towards the company. Been holding since emblem days and so frustrated with this idiotic management. Why they can’t be honest and transparent. So tire of this bs. Such a great company and potential all this bs. I always appreciate your write ups and read them all the time. They are very helpful and it takes time out of your personal life.
I agree FUN, they are evolving but slower than I had hoped.
I did also like the EBITDA numbers.
They made mor in the last quarter than they did all last year. When looking at the loss don’t have a heart attack. The loss was just a write down of the “goodwill” from the purchase of Emblem and another company. Like Mr Wonderful says “ you can not expect a new company to have a good balance sheet. Show me an increase in revenue quarter over quarter and year over year and I am happy. This makes me happy with my investment choice and Im glad Im in early.
03/25/2021 07:16 AM ET
* Press Release: Aleafia Health Reports 2020 Year End Results, Record Quarterly Revenue
Aleafia Health Reports 2020 Year End Results, Record Quarterly Revenue
-- 233% increase in Q/Q cannabis net revenue
-- $4.3 million positive adjusted EBITDA in Q4 2020
-- 42% and 501% increase in Q/Q medical cannabis and adult-use net revenue,
respectively
-- Significant product portfolio expansion with 31 new SKUs launched since
October
TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) ("Aleafia Health" or the "Company") is pleased to report its financial results for the 2020 fourth quarter ("Q4 2020") and fiscal year ("FY 2020").
"Following the successful licensing of all three of our production facilities in 2020, we've now introduced innovative new cannabis derivative and dried flower formats under a distinct and compelling brand family," said Aleafia Health CEO Geoffrey Benic. "Our expanded product portfolio is having an immediate impact, with record quarterly revenue and strong sequential growth in our priority adult-use, medical and international cannabis sales."
"Notwithstanding certain non-cash, one-time expenses, our focus on disciplined, profitable growth has paid dividends with our first year of positive adjusted EBTIDA. The commercialization of our business is rapidly accelerating with the shift in revenue mix towards the sale of highly profitable packaged cannabis products providing a sustainable source of continued growth."
CONDENSED INCOME (LOSS) STATEMENT
Three months ended Year ended
Dec
Dec 31, Sep 30, 31, Dec 31, Dec 31,
($,000s) 2020 2020 2019 2020 2019
Net revenue 15,203 4,967 6,028 44,542 16,351
Cannabis net
revenue(1)(3) 14,122 4,244 4,852 41,088 11,628
Adjusted gross
profit before
fair value
("FV")
adjustments on
net cannabis
revenue 8,365 355 3,864 23,357 4,884
Adjusted gross
margin before
FV adjustments
on net
cannabis
revenue((1) 59% 8% 80% 57% 42%
Selling,
general &
administrative
expenses
("SG&A") 7,909 6,737 5,924 29,248 30,553
Gross profit (3,867) (10,001) 5,542 (5,610) 20,782
Adjusted
EBITDA(1)(2) 4,320 (5,153) (763) 8,996 (19,574)
--------------- -------- ------- ------ -------- -------
Net loss (217,301) (19,762) (9,759) (247,238) (39,607)
-------- -------
1. See "Cautionary Statements Regarding Certain non-IFRS
Measures" section of associated MD&A for term definition.
2. See "Adjusted EBITDA" section for reconciliation
to IFRS equivalent.
3. See "Revenue" section for reconciliation to IFRS
equivalent.
ADJUSTED EBITDA & NET INCOME
Three months ended Year ended
Dec 31, Sep 30, Dec 31, Dec 31, Dec 31,
($,000s) 2020 2020 2019 2020 2019
----------------- --------- -------- ------- --------- ----------
Net loss (217,301) (19,762) (9,759) (247,238) (39,607)
Deferred income
tax expense
(recovery) 2,854 (4,394) 3,616 (2,540) 2,959
Share-based
payments 582 648 929 2,690 13,512
Business
transaction
costs 824 816 1,630 4,146 5,212
Depreciation and
amortization((1) 2,651 3,273 2,200 10,166 5,912
Bad debt expense 988 500 - 1,892 -
Interest expense 3,098 3,062 1,661 11,636 5,959
FV changes in
biological
assets and
changes in
inventory sold 11,106 10,708 (1,041) 29,133 (13,219)
Intangible asset
write-down 22,116 - - 22,116 -
Goodwill
write-down 177,476 - - 177,476 -
Non-operating
expense
(income) (74) (4) (1) (481) (302)
------
Adjusted
EBITDA((2) 4,320 (5,153) (763) 8,996 (19,574)
----------------- -------- ------- ------ -------- -------
1. Q4 2020 includes $2.1M non-cash depreciation expensed
to cost of sales.
2. See "Cautionary Statements Regarding Certain non-IFRS
Measures" section of associated MD&A for term definition.
CANNABIS OPERATIONAL RESULTS
Q4 2020 Q3 2020 Q4 2019 FY 2020 FY 2019
--------------------------------- ------- ------- ------- ------- -------
Cannabis net revenue(1)(2) 14,121 4,245 4,852 41,088 11,628
Net medical cannabis
revenue(1)(2) 2,717 1,909 1,731 7,950 4,361
Net adult-use cannabis
revenue(1)(2) 1,409 235 554 3,221 4,116
Net bulk wholesale cannabis
revenue(1)(2) 9,995 2,101 2,805 29,915 3,390
Active, registered patients 18,740 17,526 10,249 - -
------- -------
1. See "Cautionary Statements Regarding Certain non-IFRS
Measures" section of the associated MD&A for term
definition.
2. See "Revenue" section of the associated MD&A for
reconciliation to IFRS equivalent.
-- Medical cannabis net revenue for Q4 and FY 2020 was $2.7 million and $8.0
million, an increase of 57% and 82%, respectively, over the same periods
in the prior year. The increase was primarily due to improved product
offerings and a continued increase in the Company's total number of
active, registered patients. Management believes that the Company's broad
medical cannabis ecosystem, which includes clinics and scheduled same day
delivery, in addition to cannabis products, provides the company with a
core competitive advantage.
-- Net adult-use cannabis revenue for Q4 and FY 2020 was $1.4 million and
$3.2 million, respectively, compared to $0.6 million and $4.1 million for
the same periods in the prior year, and $0.2 million during the three
months ended September 30, 2020 ("Q3 2020"). The sequential increase was
primarily due to greater product availability, including the launch of
new product formats and SKUs.
-- Net bulk wholesale revenue received from sales to cannabis licensed
producers (each an "LP") for Q4 and FY 2020 was $10.0 million and $29.9
million, an increase of 256% and 783% respectively, over the same periods
in the prior year. The increase was primarily due to the sale of flower
harvested at the Port Perry Facility's outdoor cultivation site to other
LPs, and a larger harvest in 2020 relative to the prior year, yielding
31,200 kgs of dried flower.
Adjusted EBITDA for Q4 and FY 2020 was $4.3 million and $9.0 million compared to losses of $0.8 million and $19.6 million, respectively, in the same periods in 2019, and a sequential improvement of $9.4 million over the previous quarter. The substantial difference in quarterly adjusted EBITDA reported over the course of 2020 is primarily due to the seasonality of outdoor cultivation associated sales, which provide a substantial contribution margin. Bulk wholesale revenue fluctuated significantly over the course year, which significantly effects adjusted EBITDA and net income or loss.
Net loss for Q4 and FY 2020 was $217.3 million and $247.2 million, compared to losses of $9.8 million and $39.6 million in the same periods in 2019. In both Q4 and FY 2020, the net loss was primarily due to non-cash items including a fair value changes in biological assets and changes in inventory sold expense of $11.1 million for the quarter and $29.1 million for the full year. Included in the full year amount is a $17 million write-down to net realizable value of saleable inventory to reflect declining wholesale prices.
During Q4 2020, the Company incurred a $22.1 million write-down of intangible assets expense. This includes a $10.6 million write-off associated with the Company's 51% interest in the Flying High Brands joint-venture, as the Company is now primarily developing its brands and products in-house, rather than licensing them from other cannabis companies.
The Company also wrote-down $176.0 million of goodwill associated with the acquisition of Emblem Corp., and $1.4 million of goodwill associated with the acquisition of Canabo Medical Corp.
PRODUCT PORTFOLIO & SALES GROWTH
With the receipt of necessary Health Canada licences received earlier in 2020, the Company began the development and production of a number of new product formats and existing line extensions, with launches commencing in Q4 2020. The launches have resulted in an increase of 31 cannabis products SKUs since October, directly impacting the increased sales in both markets.
-- Sublingual Strips: Kin Slips, the cannabis-infused sublingual strips,
launched in Q4 2020 in the medical and adult-use markets. Kin Slips
offers a fast onset time relative to other non-combustible cannabis
products. Placed under the tongue, the active ingredients enter the
bloodstream through the sublingual gland, delivering a typical onset time
of 10 to 15 minutes (though individual experience may vary).
-- 510 Vape Cartridges: The vapes are inspired by Aleafia Health's signature
cultivars and contain custom-made, unique terpene blends deliver robust
flavours and consistent effects. They contain CO2-extracted distillate
mixed with a custom blend of botanically sourced terpenes. No fillers or
artificial flavours are used in the vapes, which were launched in Q4
2020.
(MORE TO FOLLOW) Dow Jones Newswires
March 25, 2021 07:16 ET (11:16 GMT)
Press Release: Aleafia Health Reports 2020 Year -2-
-- Confectionary Edibles: Subsequent to the reporting period, the Company
released THC soft chews, its first cannabis edible product. Soft chews
are currently the largest edibles category in Canada, as they are in
other international jurisdictions with a more established legal adult-use
cannabis market. The initial launch features two SKUs, each with two five
milligram chews per package. The Company is currently considering a soft
chews line extension to include additional flavours, and a CBD dominant
offering.
-- High Potency CBD Oil: In December, the Company launched a high potency
cannabis oil, CBD 50, with 50 mg per millilitre of CBD oil, provides
greater consumer and patient convenience and has more than twice the
potency of traditional high CBD oils.
-- Exclusive Cultivars: The Company's medical cannabis patients now benefit
from access to highly sought-after strains through its supply agreement
with cannabis brands house Robes Cannabis Inc. (dba as BLLRDR). As part
of this agreement, subsequent to the reporting period, the Company
launched the Afghani Bullrider and Wedding Cake strains each in 3.5 gram
containers.
-- Dried Flower at Scale: Leveraging the greater scale of cultivation
capacity, the Company has also expanded upon its signature strains with
greater product availability, and new larger format SKUs, including a
pre-roll line extension with 12 pre-rolls each of 0.35 grams. Initial
purchase orders for this and other new dried flower SKUs have commenced
shipping to adult-use provincial wholesalers beginning in March.
CONFERENCE CALL & WEBCAST
Date: March 25, 2021
Time: 8:30 a.m. EST
USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 3497836
International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 3497836
WEBCAST LINK
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. Participants who miss the live call can view a replay at any time via the link provided.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
My thoughts have not changed.
Aleafia is evolving.
It would be sad if they already sold off all of the outdoor grow for wholesale.
They already said that they are going to use their own outdoor grow for Cannabis 2.0 products.
If so, those command higher profit margins.
They are ramping up everything that they brought out in Q4 and Q1.
Q1 may be able to beat the Q4 revenues.
That we will have to wait for.
They sure guided us correctly on Q4.
Too bad with Q1 nearly over they didn’t indicate much pride.
The best news was strong EBITDA profits.
That's a so, so report FUN and ty for breaking it down for us. I suspect we'll be hanging out in this range for a bit.
Earnings Call Transcript - (See Blue & Red highlights) Aleafia Health Inc. (ALEAF) CEO Geoffrey Benic on Q4 2020 Results - Earnings Call Transcript
Mar. 25, 2021 12:13 PM ETAleafia Health Inc. (ALEAF)
https://seekingalpha.com/article/4416038-aleafia-health-inc-aleaf-ceo-geoffrey-benic-on-q4-2020-results-earnings-call-transcript?mail_subject=aleaf-aleafia-health-inc-aleaf-ceo-geoffrey-benic-on-q4-2020-results-earnings-call-transcript&utm_campaign=rta-stock-article&utm_content=link-2&utm_medium=email&utm_source=seeking_alpha
Company Participants
Nick Bergamini - Vice President, Investor Relations
Geoffrey Benic - Chief Executive Officer
Benjamin Ferdinand - Chief Financial Officer
Conference Call Participants
Rahul Sarugaser - Raymond James
Operator
Good day and welcome to Aleafia Health Fourth Quarter 2020 and Year End Results Conference Call. I would now like to turn the conference over to your host, Nick Bergamini, VP of Investor Relations. Please go ahead.
Nick Bergamini
Thank you. Joining me on the call today are Aleafia Health CEO, Geoffrey Benic; and CFO, Benjamin Ferdinand.
This morning, Aleafia Health filed on SEDAR’s audited financial statements and notes thereto for the year ended December 31, 2020 and its associated MD&A. All comments we made on this call today should be taken with reference to and are qualified in their entirety by those documents. Please note that this call contains forward-looking statements or information and reflects the company’s current expectations, estimates, projections, assumptions and beliefs about future events and financial trends that they believe may affect the company’s financial condition, results of operations, business strategy and financial needs. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements or other future events to be materially different from any future events, performance or achievements expressed or implied by such forward-looking statements.
Given these risks and uncertainties, shareholders and prospective purchasers of the company’s securities should not place undue reliance on these forward-looking statements. Further, they speak only as of the date on which such statement is made and except as required by applicable law the company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made. This call also contains non-IFRS financial performance measures, which the company believes provides users with relevant information regarding operations and performance. These measures are not recognized or defined under IFRS and as a result, they may not be comparable to the data presented by other issuers.
Geoffrey, over to you?
Geoffrey Benic
Thank you, Nick and thanks everyone for joining us today. It’s exciting to see how far we have come over the last 2 years. 2019 saw us build out our three production facilities. During 2020, we secured the licenses for these sites, while immediately shifting our focus to the development of differentiated cannabis products and brands. It’s in the fourth quarter that we are just beginning to see the results from this groundwork we have laid over the last 2 years.
Putting things in perspective, our net cannabis revenue has increased from $600,000 in 2018 to $11 million in 2019 to $41 million in 2020.
Capping this off is our strongest sales quarter-to-date, with $14 million in net cannabis sales. And this was driven by growth through all four channels of international, medical, adult-use and domestic wholesale. But what’s most important is that 2020 saw us commence what is a major expansion of our product portfolio.
As a result, we are beginning to see what will be a significant recalibration of our revenue away from domestic wholesale and towards the sale of packaged cannabis products.
I know Ben will discuss in greater detail, but I will touch on the non-cash accounting write-downs, which clearly impacted the net loss in the quarter, but it’s important to note that these are accounting non-cash, non-recurring write-downs of intangible assets or goodwill. These have no impact on our cash profitability and they are not associated with the winding down of any facilities or other physical assets. It’s something that many of our peers have also gone through.
And with that behind us, we are in a great position for continued growth. Removing these non-cash items, we have realized our first annual positive adjusted EBITDA of $10 million on the year compared to a loss of $20 million in 2019. With the licensee bottleneck removed, our team did an excellent job developing new products, including some highly differentiated formats. Since the launch of vapes, we have delivered a total of 9 new product formats or significant line extensions.
Since October, we have launched a total of 31 new SKUs, many of which are sold in both medical and adult-use markets. Given what we started 6 months ago, this is quite an achievement from our team and something that really speaks to the executional capabilities.
During Q4, we launched high potency CBD oil 510 vape cartridges in cannabis-infused sublingual strips. Though sales of these products in the adult-use market only commenced in December, we are already beginning to see the impact as we saw a 500% sequential increase in recreational sales over Q3 driven by these new formats. This should significantly impact 2021 Q1 revenues for the betterment given 3 full months vs 1 month. - FUNMAN
In Q1 of this year, so far, our sublingual strips, Kin Slips, were a top selling product format and CBD 50 was our top selling individual product SKU. And recently, we launched THC soft chews, our first cannabis edible format. Of even greater importance though is that much more recent expansion of our dried flower portfolio. This obviously remains the most important category in Canada by a wide margin. Again, given that not of these product revenues are included in 2020 Q4 numbers, this bodes well for the Q1 report. - FUNMAN
This month, we commenced shipments of several new dried flower SKUs, including pre-rolls from our outdoor cultivation harvest. Rounding out the product front is the imminent launch of our wellness line, Noon & Night. This is a highly differentiated brand that features formats that are familiar to consumers in non-cannabis form, but which often are not yet available to Canadian consumers. We have received purchase orders for the first two formats under this brand, including omega-3 softgels. We are now at the point where we have an incredibly diverse product portfolio, but the consistent theme is that we have focused on areas of key competitive advantages, whether that is through novel formats, quality or pricing. This sounds great, and again, revenues from these products won't be realized until 2021 Q1 and many not until Q2. - FUNMAN
On the international front, we have also made some significant headway. In December, we announced that our Niagara Greenhouse was deemed EU GACP compliant. Why that’s important is that means flower grown at our greenhouse is eligible to be exported to European Union and other international markets, with the caveat that it must be driving shipped from an EU GMP certified facility. And we have a strategic partner that does that for us. Since that time, we have sent batches to Germany for stability, quality and cannabinoid testing and the well-being to meet EU GMP standards. We are now in the final stages of beginning exports to the EU, with securing the customary import and export permits.
Similarly, we received an export permit earlier this week for our greenhouse flower to be exported to the UK. Obviously, the international channels are filled with red tape and take time, but most of the heavy lifting is done and we are excited to commence our first exports to new countries in Europe in the near future. The UK, Germany and Israel might add some meaningful revenues to 2021 Q2 and beyond. But, it doesn't appear that they have customers lined up except in Israel. - FUNMAN
We also completed our largest international shipment ever to Australia in Q4. We may start to see more regularity in orders from our customers there as we merely received a larger purchase order in January and are just waiting for the export permits now.
Lastly, I will touch on our agreement with Unifor, Canada’s largest private sector union, which has 315,000 members. For American shareholders, Unifor would be the equivalent of the UAW in the U.S. The purpose of this agreement is to gain insurance coverage for medical cannabis for union members and their immediate family members. Unifor has shown great leadership in advancing this cause, which is fundamentally about patient access to medicine. We now have one of the Canada’s largest employers signed on to the program with their employees and family members soon becoming eligible to spend $500 per year per person on medical cannabis through their insurance plans. Putting this in perspective, if only 15% of UNIFOR members (47,250) opt for reimbursement of $500 annually, that's a sweet $23,625,000 bump in Aleafia's annual revenues. I use the 15% number because ... - FUNMAN
That was a Terrible conference Call, they didn't give actual Numbers they talked Percents, we've always heard Patient numbers!! They only talked about Unifor and it was $500.00 of coverage per year, per Patient, that seems a bit out of Wack.. They Lacked any color on everything... the Q-1 will be less then Last years Q-1. One Analyst was on the call and asked 3-Questions and the call was Over... Good Day.
Ndakota
Point taken
Hopefully The Street is happy. (See Blue & Red) --->>> Aleafia Health Reports 2020 Year End Results, Record Quarterly Revenue
Aleafia Health Reports 2020 Year End Results, Record Quarterly Revenue
https://financialpost.com/globe-newswire/aleafia-health-reports-2020-year-end-results-record-quarterly-revenue
I hope not too. They have been doing what they say they will. They were one of the first to market with vapes, their kinslips are amazing, they have decent flower. They just rolled out Bogart’s kitchen gummy line, they are one of the few canadian companies that has a good balance sheet. I think this financial announcement will provide clarity.
It is sure looking like no run up in anticipation of Q4 earnings coming out. Hopefully that means we will get a good bump in buying after earnings are made public.
I hope they are not doing anything shady. Been slowly losing the trust in the team. Been holding over 4 years now.
I do not know, crazy that the deal with the biggest union in the country got crickets in response. Strange times.
So low here, price and volume.... is everyone waiting for financials or just all in on the US market?
$ALEAF heavy volume day. Already broke it's avg 10 day volume.
Do y'all think we will see a run up prior to the earnings release with a sell on the news? Seen that pattern so many times. Suspect it will also depend on just how good the news.
I was actually trying to give them some info. It is impossible to advertise here in canada but there are ways to get the word out. There is a girl with some pretty severe medical issues who has gotten a great deal of help from the medical cannabis and she is kind of diarizing her experience. Not a stoner and she talks about the effects she gets from different products. Many are from Aleafia because she mentions Emblem as one of her prescriptions. I just wanted them to know about the channel. They could not pay her or anything but they could point people who are new to cannabis to someone who is navigating the system and doing personal reviews of the effects and challenges. They did not respond at all which I find very rude. I also find it poor business to not use every opportunity to advertise your product.. Word of mouth is the best advertising and she speaks highly of the products. I really do not care one way or the other but I was just surprised their response was silence.
I did not give the info since they did not answer me. Lol! You do not know what you don’t know.
I know I emailed them a while back and they did not reply until the information I was asking for was made public- It had to do with date of release of earnings report. So, from my experience, they don't reply if you are asking for information that is not yet made public.
Are you asking questions that they cannot legally answer?
Can you share some of what info youre looking for here on this board? Maybe someone here already knows.
I havent tried contacting IR as of yet.
I have left phone messages and since they say if you want a faster response to email, I have emailed and have had no response at all to either. I was very surprised
I’ve found them to be very responsive.
Every time I’ve reached out they’ve responded.
I have sometimes. It depends upon what you ask and how you ask it.
Has anyone found Aleafia’s investor relations at all responsive? That so is the only thing I have been disappointed in at all. The kinslips were incredible for a family member. Like one dose amazing!
Saskatchewan's population reached 1,177,884. With no big cities, it's not a ground breaking addition to sales potential, but it's a big plus knowing they were able to get over the regulatory hurdles.
It's also important because there are 6 more provinces with their own hurdles to go.
Aleafia's adult-use products are only reaching two thirds of Canada. That leaves some substantial growth opportunities.
Let's kick that into gear Aleafia! - FUNMAN
Aleafia Health Expands Adult-use Presence with Entrance in Saskatchewan, new Provincial Market
Aleafia Health Expands Adult-Use Presence with Entrance in Saskatchewan, New Provincial Market
http://www.globenewswire.com/fr/news-release/2021/03/16/2193528/0/en/Aleafia-Health-Expands-Adult-Use-Presence-with-Entrance-in-Saskatchewan-New-Provincial-Market.html
Thanks for the Kin Slips link. I wasnt finding them on the OCS website because I thought they were listed under Symbol brand. Duh! Hope to get a specific breakdown of revenue from Kin Slips such as do they pay a cut from each individual sale for licensing fee or did they pay a one time contract fee?
Looking forward to the earnings FUN.
Cannabis companies to report earnings: Village Farms on March 16, followed by Green Thumb Industries on March 17, Hexo Corp. and Sundial Growers on March 18, TerrAscend Corp. on March 23, and Aleafia Health, Cresco Labs and Charlotte’s Web on March 25.
Yeah, like that 7 mil stolen from $ALEAF.
No idea but maybe we'll find out on the next report?
I’ve patronized 6 One Plant stores over the past year. I’ve visited/purchased from 4 local competitors as well.
The One Plant stores were/are most impressive.
https://www.oneplant.ca/stores/
All were very customer service oriented
To be fair the others were as well but not as organized.
The governmental involvement up here has/had truly stifled many but the strong have survived.
I spoke to various managers and owners and each confirmed that store sales and traffic have increased monthly even during our ever changing lockdown rules.
Emblem products are well accepted and continue to have loyal buyers.
Kin Slips are selling well.
https://ocs.ca/collections/kin-slips?product=5795899213644&load_view=load&sort_by=products_price_per_uom_as
GLTA
We’ve heard about big busts at illegal cultivators. It’s the big distributor crime lords that need to be taken down.
Aleafia owns 10% of One Plant. I wonder how the accounting works?
I think they have been trying to crack down on illegal sales for some time and it's beginning to pay off for retailers.
They were a bit behind schedule but better late than never. One would think they are buying quite a bit of ALEFIA products.
More sales stats --->>> Ontario’s legal weed market share climbs to 40%, OCS says
Ontario led all provinces in Q4 with $251 million in legal weed sales, according to the OCS's latest quarterly report
By: Jared Gnam
March 8, 2021
Good luck with your new shares. I have no idea which company MF is referencing at the bottom of the article. The link takes you to another form to register. I choose not to proceed further.
I added $.54 this week. Is this little know Canadian company MF talking about at bottom of this article?
https://www.fool.com/investing/2021/03/11/why-these-marijuana-stocks-blasted-higher-today/
An even dozen open stores, with another 11 opening by the end of summer. I sure hope One Plant is buying lots of Aleafia's products.
I think I'm gonna need to add here soon. Giddy back up Aleafia!
I thought I remembered Israel mentioned but maybe there is something different here.
Or everyone who owns shares in the company could spend time spreading the word it exists and buy their product. That would improve their fins enormously. Since in canada they have a perfectly legal product they can not advertise. No rules against word of mouth. That is one thing we investors can do to help our own bottom line.
Aleafia Health to Enter Israeli Cannabis Market, Bolstering International Sales Opportunity
Three-year agreement signed with Equinox International
Shipments expected to commence in Q1 2021, marking Aleafia’s fourth country with products in market
Israel is largest net importer of medical cannabis globally -
Followers
|
83
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3373
|
Created
|
12/08/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |